Case Report: The effect of automated manual lymphatic drainage therapy on lymphatic contractility in 4 distinct cases

Introduction Automated manual lymphatic drainage therapy (AMLDT) is available for home use in the form of a pneumatic mat of 16 pressurized air channels that inflate and deflate to mimic the stretch and release action of manual lymphatic drainage therapy. Four cases (a patient with complex regional pain syndrome and lymphedema, a healthy patient, a breast cancer survivor with chronic pain, and a patient with a history of abdominal surgery) underwent near-infrared fluorescence lymphatic imaging (NIRFLI) with AMLDT to evaluate the effect of AMLDT on lymphatic pumping and pain. Methods Each patient received 32–36 injections of 25 μg indocyanine green (ICG) on the anterior and posterior sides of their body and underwent 1 h of NIRFLI to assess the drainage of ICG laden lymph toward regional nodal basins at baseline. Each patient lay supine on the mat for 1 h of AMLDT with NIRFLI to assess lymphatic flow during treatment. A final NIFRFLI assessment was done 30–60 min posttreatment with the patient in the supine and prone position. Patients reported baseline and posttreatment pain using the Visual Analogue Scale. An imager analyzed NIRFLI images using ImageJ (US National Institutes of Health). Using time stamps of the first and last images to determine time lapsed and the number of pulses observed in a timeframe, pulsing frequency (pulses/min) was obtained to assess lymphatic function. Results All 4 cases completed the NIRFLI and AMLDT without complications; all 3 patients with baseline pain reported reduced pain posttreatment. AMLDT appeared to alter lymphatic contractility, with both increased and decreased pulsing frequencies observed, including in nonaffected limbs. Pulsing frequencies were very heterogeneous among patients and varied within anatomic regions of the same patient. Discussion This proof-of-concept study suggests that AMLDT may impact lymphatic contractility. Further research on its effect on lymphatic function is warranted.

Introduction: Automated manual lymphatic drainage therapy (AMLDT) is available for home use in the form of a pneumatic mat of 16 pressurized air channels that inflate and deflate to mimic the stretch and release action of manual lymphatic drainage therapy.Four cases (a patient with complex regional pain syndrome and lymphedema, a healthy patient, a breast cancer survivor with chronic pain, and a patient with a history of abdominal surgery) underwent near-infrared fluorescence lymphatic imaging (NIRFLI) with AMLDT to evaluate the effect of AMLDT on lymphatic pumping and pain.Methods: Each patient received 32-36 injections of 25 μg indocyanine green (ICG) on the anterior and posterior sides of their body and underwent 1 h of NIRFLI to assess the drainage of ICG laden lymph toward regional nodal basins at baseline.Each patient lay supine on the mat for 1 h of AMLDT with NIRFLI to assess lymphatic flow during treatment.A final NIFRFLI assessment was done 30-60 min posttreatment with the patient in the supine and prone position.Patients reported baseline and posttreatment pain using the Visual Analogue Scale.An imager analyzed NIRFLI images using ImageJ (US National Institutes of Health).Using time stamps of the first and last images to determine time lapsed and the number of pulses observed in a timeframe, pulsing frequency (pulses/min) was obtained to assess lymphatic function.Results: All 4 cases completed the NIRFLI and AMLDT without complications; all 3 patients with baseline pain reported reduced pain posttreatment.AMLDT appeared to alter lymphatic contractility, with both increased and decreased pulsing frequencies observed, including in nonaffected limbs.Pulsing frequencies were very heterogeneous among patients and varied within anatomic regions of the same patient.Discussion: This proof-of-concept study suggests that AMLDT may impact lymphatic contractility.Further research on its effect on lymphatic function is warranted.

Introduction
The lymphatic system is an essential part of the vascular system, with multitasking functions to absorb fats and fat-soluble nutrients in the digestive system; eliminate excess extravasated fluid from blood vessels as part of homeostasis; and facilitate immune responses by surveilling pathogens and enabling immune cell transit within lymph fluid (1)(2)(3)(4)(5)(6).Dysfunctional lymphatic vessels and/or lymph nodes can result in build-up of lymph fluid in the interstitial space, resulting in lymphedema (LE), which initially manifests as edema in the extremities and progresses to fibrosis, with eventual impaired limb function, pain, depression, and increased cellulitis risk.From 2012 through 2017, there were more than 165,000 hospital admissions due to LE, 92% of which were associated with cellulitis in the United States (US) (7).While primary LE is genetic, most cases are secondary and related to obesity, or acquired following radiotherapy, surgery, trauma, or infections.Approximately 15.5% of breast cancer survivors develop LE, with 24% having LE 7 years postdiagnosis (2,8,9).Decreased lymph flow leads to the accumulation of proinflammatory cytokines that continuously activate nociceptors responsible for pain, resulting in a chronic inflammatory response that can be associated with chronic pain and disease (4)(5)(6).Chronic rheumatoid arthritis (RA) and complex regional pain syndrome (CRPS) appear to be associated with impaired lymphatic function (4,(10)(11)(12).
Therapy targeting LE aims to reduce lymphatic fluid in the affected limb to improve function and prevent progression (2,(13)(14)(15).The most widely accepted treatment is complex decongestive therapy (CDT), which primarily involves a specialized gentle type of therapeutic massage known as manual lymphatic drainage (MLD), followed by exercise, compression therapy, and skin care (1,2,13,14).Randomized controlled trials (RCTs) have demonstrated statistically significant improvements in the incidence of LE and pain following MLD in patients with breast cancer (p = .02)(15).Pneumatic compression therapy (PCT) is part of CDT and usually involves a garment inflated by a pump over the affected limb to mimic MLD in the home setting (16).Multiple studies have demonstrated that significant edema reduction occurred with PCT (16)(17)(18)(19).
Over the past decade, improved techniques in lymphatic imaging have demonstrated lymphatic contractile function following LE treatment.Near-infrared fluorescence lymphatic imaging (NIRFLI) visualizes lymphatic function and movement in real-time, by tracing the flow of intradermal injections of indocyanine green (ICG) administered to relevant anatomic sites (6,16,(20)(21)(22)(23)(24).NIRFLI has shown that lymphatic function improves following MLD (21) and PCT (16,23,24).However, while improved lymphatic pumping, measured by increased pulsatile frequencies of lymphatic vessels, has been consistently observed with NIRFLI, lymphatic mapping of drainage patterns is highly heterogeneous and variable from one patient to the next, even among the same affected anatomic regions (25).Lymphatic vessels can both converge into one and split into multiples at the same site, and their drainage pathways and rates vary enormously.
A novel PCT medical device is now available over the counter for home use that involves a 16-chamber mat on which patients lie down supine to receive automated MLD therapy (AMLDT).The US Food and Drug Administration classifies it as a Class II medical device indicated for temporary pain reduction in people with good health, excluding pregnancy, heart/vascular problems, acute pulmonary edema, infections, injury at/near the application site, where increased venous/lymphatic return is undesirable, spinal cord/back injuries, and bronchial asthma.Herein, 4 case reports describe a patient with traumatic CRPS and LE, a healthy patient, a breast cancer survivor with chronic pain, and a patient with a history of abdominal surgery.They serve as proof of concept to assess how AMLDT impacts lymphatic function and also demonstrate their unique lymphatic drainage patterns.Each case underwent NIRFLI while receiving a single session of AMLDT to determine whether AMLDT improved lymphatic pumping, specifically pulsatile frequency.Secondarily, patient feedback on AMLDT and its effect on pain was assessed to understand patient perspective.

Case description
All 4 patients presented at a university outpatient clinic in August 2023 and provided their written informed consent.The Committee for the Protection of Human Subjects approved the study protocol (HSC-MS-23-0093) on June 22, 2023.In all cases, vital signs were normal at time of presentation.

Case 1
A 58-year-old, White male patient presented with CRPS and stage 1 LE on the right calf and foot.He had no relevant family history and had been taking diosmin/hesperidin and Vitamin C, D3, and B-complex supplements for 2 years.He was in a motor vehicle accident in 1997, resulting in a complex right ankle and tibia/fibula fracture and compartment syndrome.He underwent 16 surgeries over a 3-week period, including external fixator placement, 4-compartment fasciotomy, debridement, skin grafting, and bone grafting.The CRPS was initially managed with lumbar sympathectomies, pain medications, and acupuncture therapy.At the time of presentation, he used physical exercise and compression stocking to manage the CRPS symptoms.

Case 2
A 54-year-old, healthy, White Hispanic male patient presented with no relevant history; he had no chronic pain or LE.He underwent right Achilles tendon repair in 1985 and abdominal hernia repair in 2008.He underwent a left partial thyroidectomy in 2005 and took levothyroxine for 23 years.

Case 3
A 71-year-old, White female, 30-year breast cancer survivor presented with RA, chronic back pain due to degenerative joint disease, and mild scoliosis.Medications included lisinopril, a statin, levothyroxine, antidepressants, pantoprazole, hydroxychloroquine and supplemental vitamins, turmeric, and probiotics.Chronic pain was managed with gabapentin, naproxen, and tizanidine.She underwent a lumpectomy of the left breast in 1992 and had a history of non-Hodgkins lymphoma from 2015.She had titanium rods in both femurs due to previous fractures in 2007, with additional right femur hardware revisions in 2014 and 2016.She sustained multiple fractures to her arm in 2017 and 2018.Her RA had been managed monthly for the past 20 years with an immunomodulating drug.

Case 4
A 64-year-old, White female presented with a history of cosmetic abdominoplasty and brachioplasty (3 years prior).She had mild hypertension, managed with daily losartan, Hashimoto's thyroiditis, and a history of obesity, which resolved following Roux e Y gastric bypass 18 years prior.Medications included thyroid supplementation, postmenopausal estrogen replacement, and botox injections to the scalp every 3 months for migraines.

NIRFLI procedure
Each case underwent a NIRFLI session with concurrent AMLDT.NIRFLI assessed lymphatic flow at baseline with the patient in a supine and prone position, during 1 h of AMLDT with the patient in a supine position, and 30-60 min posttreatment with the patient in a supine and prone position.At the start of the imaging session, patients reported pain using a Visual Analogue Scale (VAS, based on a score between 0 and 10, with 0 having no pain and 10 having the most pain).Each patient put on a "bikini" bottom, and women wore a bikini top, to afford maximal visualization of dermal lymphatic regions.
The ICG (25 mg vial) was reconstituted with 10 ml sterile water and further diluted in sterile saline immediately prior to administration.The final concentration of 0.32 mM provided 25 μg ICG/injection, with each injection of 0.1 cc made at the anatomical injection sites shown in Figure 1.Tables 1, 2 also describe the anatomic injection sites of each case.Alcohol wipes were used to clean each injection site before intradermal injection.Each patient received 32-36 injections.NIRFLI was accomplished using a custom system consisting of a Gen III military-grade intensifier coupled to a frame transfer, 16-bit camera with 200 ms exposure times (20).Initial NIRFLI imaging lasted for 60 min to assess the drainage of ICG laden lymph from each injection site toward regional nodal basins.Vital signs of blood pressure, pulse rate, respiratory rate, temperature, and redness or inflammation at the injection site were monitored and recorded at baseline (before ICG injection) and 15 and 30 min after injection.NIRFLI imaging continued during the 1-h AMLDT session.After AMLDT, imaging continued for another 30-60 min.Patients reported any posttreatment pain and provided their feedback on the AMLDT device.

NIRLFI analysis
A trained imager from the molecular imaging center analyzed NIRFLI images using ImageJ (US National Institutes of Health).Movies were generated from sequences of NIRFLI and depicted movement of lymphatic vessels and lymph nodes.A region of interest (ROI) was chosen along each lymphatic vessel, and the The injection protocol for Case 1, a 58-year-old male patient with complex regional pain syndrome and stage 1 lymphedema (LE) in his right foot and calf is depicted in 1A.The protocol for Case 2, a 52-year-old, healthy male patient with no relevant history of LE is shown in 1B.The protocol for Case 3, a 71-year-old breast cancer survivor with chronic pain from rheumatoid arthritis and degenerative joint disease and a history of LE is shown in 1C.The protocol for Case 4, a 64-year old female patient with a history of abdominoplasty and brachioplasty that caused prior LE is shown in 1D.increasing/decreasing fluorescence intensity associated with each pulse observed as it moved through the ROI in successive movie frames.The timelapse was determined from the time stamps of the first and last images in each movie.The number of pulses observed in each vessel ROI was divided by the corresponding timelapse to render pulsing frequency (pulses/min) for each vessel, which is an outcome measure of lymphatic function (20).The investigators only had a 2-day period to evaluate all 4 cases, when at least 4 days were needed to collect complete timepoint data.Given these time constraints due to laboratory availability, it was necessary to omit some timepoints from data collection and analysis.Thus, the investigators focused on the back and trunk, as well as areas of interest specific to each case (such as the first case's foot with CRPS).All relevant data were collected in an Excel spreadsheet.

AMLDT procedure
The AMLDT system (Neuroglide, Eva Medtec, Bloomington, MN) offers 3 treatment focus zones (Upper and Lower Back/Neck, Upper Back/Neck, and Lower Back) and 3 pressure settings (mild, medium, and intense).The back/neck pad has 16 air channels precisely timed to produce a sequential inflation/deflation pressure cycle, mimicking the stretch and release action provided by therapeutic MLD-like massage to manipulate soft tissue, relieve pain, and increase circulation.The AMLDT system is intended for use on a flat, firm surface at home.
Each patient lay supine on the pad with their heads centered on the supportive pillow section, ensuring that there were no gaps between their neck and the pad.They received 1 h of intense AMLDT to the upper and lower back/neck.

Results/cases 1-4
All 4 cases completed the NIRFLI and AMLDT session without complications or adverse events.Tables 1, 2 report the lymphatic pulsing frequencies for visualized vessels draining at each injection site (listed in top down order as depicted in Figure 1) 1 h before AMLDT, during treatment, and 30-60 min posttreatment.When multiple vessels drained at an injection site, a pulsing frequency for each is reported.AMLDT appeared to alter lymphatic contractility; both increased and decreased pulsing frequencies were observed, including in healthy, nonaffected limbs (Case 2).Pulsing frequencies were very heterogeneous from one case to the next and also varied within anatomic regions of the same patient.Figure 2 shows avatar examples of the heterogeneity of the directional changes in pulsing frequencies on the backs of each case.
In Case 1, NIRFLI demonstrated lymphatic dysfunction with dermal backflow, in which lymph moves into the lymphatic capillary bed instead of unidirectionally into lymphatic collector vessels, and tortuous vessels in the right upper lateral shin and foot.Generally, injection sites on the arms, anterior abdomen, and anterior legs of the front of his body saw increases in pulsatile frequency during AMLDT and posttreatment, compared to baseline values (Table 1).Most notably, in the CRPS-affected right leg, the pulsatile frequency nearly doubled during AMLDT from 0.53 pulses/min to 0.96 pulses/min and remained higher than baseline during posttreatment NIRFLI (0.75 pulses/min).At the umbilical region, drainage patterns varied, with the inferior umbilical injection sites and possibly the left superior injection site draining to the inguinal region, while the right superior umbilical injection site drained towards the axilla.On his back, the injections at the thoracic level drained inferiorly and laterally and then traveled anteriorly towards axilla.Supplementary Videos 1A and 1B depict NIRFLI before and after AMLDT on his back, where lymphatic collectors traveled from medial-to-lateral in a dermatomal pattern and pulsatile frequencies decreased after treatment, except in the 2nd to 4th lumbar areas where no data was obtained (Table 2).
Case 2 (healthy patient) had increases in pulsatile frequencies on his arms, thighs, and lower legs in response to treatment (Table 1).Most notably, pulsatile frequency more than tripled in his right arm from 1.84 pulses/min before AMLDT to 5.82 after treatment.On the back, however, pulsatile frequencies generally decreased after treatment, except for his right lumbar area, where the rate tripled from 0.39 pulses/min before treatment to 1.17 pulses/min after treatment (Table 2).
Case 3 notably had a lack of pulsing or lack of data at most injection sites at the umbilical region, legs, and back, and (particularly) near the anterior and posterior neck (Tables 1, 2).One small, unusual vessel was observed on her left arm, which previously experienced a fracture and was the side corresponding to her breast cancer.Her middle umbilical-to-axilla sites saw sharp decreases in pulsatile frequencies after AMLDT, while sites on her right leg and right posterior thoracic area increased.
NIRFLI did not show pulsing on the umbilical sites of Case 4, expect for one tortuous vessel that was captured on the left lower  1).Pulsing frequencies notably increased on both her arms during and after treatment, with the posttreatment rates 3.5 higher in her right arm and 2.6 times higher in her left arm compared to baseline.In her legs, however, pulsatile frequencies decreased.On her back, rate increases were observed at the most superior injection at the posterior thorax on the right, both superior lumbar sites, and the left inferior lumbar site (Table 2).All other back sites demonstrated decreased rates after AMLDT, or data was unavailable.
From the patients' subjective perspective, AMLDT was reported as soothing and/or relaxing.Decreased pain was reported in the 3 cases that reported pretreatment pain.The VAS scores for Case 1 decreased from 5 to 2 after treatment, in Case 3 from 2 to 0, and in Case 4 from 4 to 0. Case 2 did not report any pain during this study.

Discussion
We describe 4 very heterogenous cases with and without LE or risk of LE, all of whom demonstrated altered lymphatic movement (as shown by NIRFLI) after 1 h of AMLDT.AMLDT provided pain relief to those affected with chronic pain.AMLDT is intended for pain relief; thus, the patient feedback in these case reports is not surprising, but a further discussion of the association of the lymphatic system with chronic pain is warranted, especially in the context of Case 1.A companion paper will explore the effect of AMLDT on his CRPS and LE in greater detail.
Pulsatile frequences increased and decreased in all cases, suggesting changes in lymphatic contractility trends, and findings were not necessarily consistent across the anatomic region of the same patient (Tables 1, 2).The decreased pulsatile frequencies generally observed on the back (Table 2, Figure 2), and the finding that back lymphatic collectors travel from medial to lateral along dermatomal patterns (Supplementary Videos 1A and 1B) was clearly demonstrated, but it is not unusual for unexpected lymphatic movements and drainage patterns to occur in both healthyappearing and unaffected anatomic regions (22,25).High-quality lymphoscintigraphy has shown that in over 3,000 patients with melanomas, the trunk of the body frequently demonstrated drainage across the body's midline (25), and superficial lymph flow moving laterally and a deep lymph flow moving medially has been reported in the back (26).With NIRLFI, improved imaging technology now captures real-time lymphatic movement, and our understanding of lymphatic movement is undergoing a paradigm shift from defining "normal" flow in healthy patients towards the observation that every patient has their own unique watershed zones that may not be static over time.This evolving evidence base will allow for more targeted therapeutic outcomes and advance personalized medicine.On the left, an avatar of the "expected" lymph drainage on the back of the body is pictured, with red arrows indicating directional flow from all injection sites summarized in Figure 1.On the right, an avatar of directional changes of pulsatile frequencies measured by near-infrared fluorescence lymphatic imaging on the back after treatment with automated lymphatic manual drainage therapy is pictured.Directional changes show the difference from pretreatment to posttreatment, when data were available.No intertreatment data were available.If there was no change in data (i.e., no increase or decrease in pulses/min posttreatment), then an equal sign is shown.The unexpected, decreased pulsatile frequencies observed in the back do not appear to be a limitation of the AMLDT pumping technique (Figure 2).What is unique to the AMLDT mat used in this study, compared to other MLD/PCT devices, is that the treatment not only has an effect upon limb lymphatic contractility, but also along the back, with the patient resting in a supine position, rather than seated (16)(17)(18)(19).We speculate that the relaxation induced by AMLDT, coupled with the gravity exertion on the back, resulted in decreased pulsatile frequencies, similar to a lower resting heart rate.Both extrinsic and intrinsic forces are responsible for lymphatic movement, with the latter driven by lymph vessel distension.The lymphangion, the pumping unit bounded by valves located along collector lymphatic vessels, is known to function similarly to the cardiac pump in the heart, by increasing intrinsic contractility to adapt to output pressure elevation in response to increased pressure and/or gravitational load, producing a systolic and diastolic phase (27)(28)(29)(30)(31).This intrinsic pumping mechanism varies contractility rates and lymph flow to respond to environmental factors and pressure gradients.Jamalian et al. ( 29) supported Guyton's subatmospheric theory, which hypothesizes that a lymphatic contraction produces a suction effect (in the presence of competent lymphatic valves) upon relaxing of decreased pressure downstream, opening the inlet valve and allowing for the filling of lymphatic fluid due to the low upstream pressure from the previous section of vessel (32,33).Therefore, the relaxation of the collecting vessel following contraction is essential to drawing fluid from the interstitium.Since our patients received AMLDT to the back, it is possible that the gravitational load moved a sufficient volume of fluid during treatment, decreasing output pressure and resulting in decreased contractility and pulsatile frequencies.Additionally, mapping of lymphatic drainage following MLD applied to improve LE of the upper back has shown that MLD essentially finds an alternative, efficient route to evacuate accumulated lymph interstitial fluid to an area not affected with LE (34).These alternative lymphatic drainage pathways are rerouted, as needed, on an individual basis, further explaining the heterogeneity of patient data.Further study of AMLDT on the back of the body is suggested to confirm these findings.
Only 4, noncomparative cases are reported in this paper, and so statistical analysis was not performed.While the cases represent different health states and LE status and may not be generalizable to the general population, they nonetheless support the heterogeneous anatomy and function of the lymphatic system that previously has been reported in the literature (22,25) and show the change in lymphatic contractility from before AMLDT (baseline) to posttreatment.Each patient only received 1 treatment session of AMLDT, and so, the long-term effect of AMLDT is unknown.In a study of 10 survivors of head and neck cancer with LE, NIRFLI demonstrated that daily use of advanced PCT for 2 weeks improved lymphatic function in all patients and eliminated or reduced dermal backflow in 6 of the 8 patients who had had backflow (23).There remains a need to better characterize the propulsion frequency over time.Future comparative studies could potentially control for time variations by imaging controls over the same timeframe, with a longer follow-up time, and in the same positions but without AMDLT.This proof-of-concept study suggests that, in addition to reducing pain, AMLDT appears to impact lymphatic contractility of the lower and upper extremities, umbilical region/trunk, and back.The resting, supine position required for AMLDT likely decreased contractility rates and lowered pulsatile frequency during and after treatment, further supporting that lymphangion pumps respond to intrinsic and extrinsic forces similar to the cardiovascular system and have varying contractile rates in response to changing environmental pressures.Further research on the effect of AMLDT on the back and on patients with LE and chronic pain is warranted.
Eva Medtec (Bloomington, MN) funded this study with an unrestricted grant and provided the AMLDT system.

Conflict of interest
CF was employed by Intellicure, LLC.JR and CF are listed as inventors on patents related to NIRFLI and may receive future financial benefit from its commercialization.MM is Chief Medical Officer for Eva Medtec.FA had no conflict of interest to declare during the study but is now an advisor to Eva Medtec.KE received consulting fees from Strategic Solutions, Inc., which was funded by Eva Medtec, for her participation in this study.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The author(s) declared that they were an editorial board member of Frontiers, at the time of submission.This had no impact on the peer review process and the final decision.

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers.Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

SUPPLEMENTAL VIDEO 1A
A video showing near-infrared fluorescence lymphatic imaging of the back before automated manual lymphatic drainage therapy of Case 1, a 58year-old, White male patient with complex regional pain syndrome and stage 1 lymphedema on the right calf.Brightness and contrast have been adjusted to help visualize dimmer fluorescent signals.The diagram in the upper left corner in the first few frames illustrates the location of the indocyanine green injection sites (x) and the imaging field of view (red circle) in the video.The yellow arrow in some frames highlights the movement of an example propulsion event from the upper injection site towards the left axilla.Lymphatic collectors are observed to travel medial to lateral on the back.For the left side of the back, at baseline, pulsatile frequencies were 1.55 for the superior back indocyanine green injection site, 1.20 for the posterior thoracic area site, and 1.55 and 0.84 for the 2 different vessels emanating from the lumbar area injection site.For the right side of the back, baseline pulsatile frequencies were 1.20 and 1.20 for 2 different vessels emanating from the superior back injection site, 1.08 for the thoracic area site, and undetermined (streaming) for the lumbar area site.

SUPPLEMENTAL VIDEO 1B
A video showing near-infrared fluorescence lymphatic imaging of the back of Case 1 after 1 h of automated manual lymphatic drainage therapy.Brightness and contrast have been adjusted to help visualize dimmer fluorescent signals.The diagram in the upper left corner in the first few frames illustrates the location of the indocyanine green injection sites (x) and the imaging field of view (red circle) in the video.The yellow arrow in some frames highlights the movement of an example propulsion event from the upper injection site towards the left axilla.Pulsatile frequencies decreased following treatment.On the left side of the back, pulsatile frequencies were 0.53, 0.95, and 1.59 and 1.16 for the respective superior back, thoracic area, and lumbar area indocyanine green injection sites.On the right side of the back, the respective pulsatile frequencies were 1.06 and 0.85, 0.85, and 0.53.

FIGURE 1
FIGURE 1Green triangles represent the indocyanine green injection sites for each case on both the front and back of their body.Near-infrared fluorescence lymphatic imaging (NIRFLI) was obtained for up to 3 h.The first hour captured lymphatic flow immediately before treatment with the automated manual lymphatic drainage mat.The second hour captured lymphatic flow while each patient underwent 1-hour of concurrent pneumatic compression therapy (PCT) with the automated manual lymphatic drainage mat.The final 30 to 60 min captured posttreatment lymphatic flow.The injection protocol for Case 1, a 58-year-old male patient with complex regional pain syndrome and stage 1 lymphedema (LE) in his right foot and calf is depicted in 1A.The protocol for Case 2, a 52-year-old, healthy male patient with no relevant history of LE is shown in 1B.The protocol for Case 3, a 71-year-old breast cancer survivor with chronic pain from rheumatoid arthritis and degenerative joint disease and a history of LE is shown in 1C.The protocol for Case 4, a 64-year old female patient with a history of abdominoplasty and brachioplasty that caused prior LE is shown in 1D.

TABLE 1
Anterior pulsatile frequencies (pulses/min) captured by near-infrared fluorescence lymphatic imaging before, during, and after treatment (txt) with automated manual lymphatic drainage therapy.Pre-txtInter-txt Post-txt Pre-txt Inter-txt Post-txt Pre-txt Inter-txt Post-txt Pre-txt Inter-txt Post-txt Injection sites are listed in top down order as depicted in Figure1.Multiple values per cell represent multiple vessels emanating from injection site.Empty cells indicate data were not applicable.ND, Not done; data not obtained, given the time constraints; NV, not visible; STR, streaming.

TABLE 2
Posterior pulsatile frequencies (pulses/min) captured by near-infrared fluorescence lymphatic imaging before, during, and after treatment (txt) with automated manual lymphatic drainage therapy on the back of the body.Pre-txtInter-txt Post-txt Pre-txt Inter-txt Post-txt Pre-txt Inter-txt Post-txt Pre-txt Inter-txt Post-txt Injection sites are listed in top down order as depicted in Figure1.Multiple values per cell represent multiple vessels emanating from injection site.Empty cells indicate data were not applicable.ND, Not done; data not obtained, given the time constraints; NV, not visible; STR, streaming.